New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric's drug candidate library CAMBRIDGE, Mass. - Enveric…
Read More
New patents expand the number and type of compounds available for development and the possible indications targeted, increasing the potential value of Enveric's drug candidate library CAMBRIDGE, Mass. - Enveric…
Read More
In vitro pharmacology studies confirmed EB-003's ability to target desired serotonergic receptors, supporting the potential of the neuroplastogenic therapeutic candidate to address difficult-to-treat mental health disorders without inducing hallucinations Analysis…
Read More
Selection of EB-003 based on research indicating its non-hallucinogenic, anxiolytic and anti-depressant properties CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the…
Read More
Presentation showcases the profile of EB-003, a non-hallucinogenic, neuroplastogenic DMT analog, which has shown positive outcomes in animal models of anxiety and depression CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB)…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, today announced that Joseph Tucker, Ph.D.,…
Read More
Enveric and Aries recently announced a Licensing Agreement for patented topical product aimed at treating radiation dermatitis, which impacts approximately two million cancer patients per year and has a market…
Read More
Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe mental health disorders Announced preclinical results confirming oral bioavailability and significant brain exposure…
Read More
Confirmation of oral bioavailability and significant brain exposure in rodent models supports expedited development of EB-003, with Investigational New Drug (IND) filing and first patient dosed expected in 2025 CAMBRIDGE,…
Read More
Aries to clinically develop and market Enveric's patented product for radiation dermatitis CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric"), a biotechnology company dedicated to the development of novel neuroplastogens…
Read More
